| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
In vitro, NSC668394 (10 μM; sham for 15 minutes) inhibits actin binding and ezrin T567 phosphorylation (IC50=8.1 μM) [1]. NSC668394 (1–10 μM; 2–6 h) prevents K7M2 skeletal growth mediated by ezrin. JM1 and JM2 dynasty cell line proliferation is severely inhibited by NSC668394 (20 μM) [2]. The horsefish (OS) cell motility phenotype on the thorax of HUVEC monolayers is diminished by NSC668394 (10 μM) [1].
|
|---|---|
| ln Vivo |
In the lung, NSC668394 (0.226 mg/kg/day; intraperitoneally; 5 days a week) inhibits ezrin-coupled peripheral OS migratory growth [1].
|
| Cell Assay |
Western Blot analysis [1]
Cell Types: K7M2 OS cells Tested Concentrations: 10 μM Incubation Duration: 6 hrs (hours) Experimental Results: Inhibits T567 phosphorylation and actin binding of endogenous ezrin without changing cellular ezrin levels. |
| Animal Protocol |
Animal/Disease Models: Female BALB/c and SCID/Beige mice were injected with K7M2 or MNNG-HOS tumor cells [1].
Doses: 0.226 mg/kg/day. Route of Administration: intraperitoneal (ip) injection, 5 days a week for 66 days. Experimental Results: Shows increased survival rates. Reduces the number of green fluorescent protein (GFP)-expressing metastases in lung tissue. |
| References |
|
| Molecular Formula |
C17H12BR2N2O3
|
|---|---|
| Molecular Weight |
452.1
|
| Exact Mass |
449.921
|
| CAS # |
382605-72-3
|
| Related CAS # |
JUN-1111;874351-38-9
|
| PubChem CID |
381594
|
| Appearance |
Orange to red solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
575.1±50.0 °C at 760 mmHg
|
| Flash Point |
301.6±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.729
|
| LogP |
3.65
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
528
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OHPHDPYJEHZGDE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H12Br2N2O3/c18-11-6-9(7-12(19)16(11)23)3-5-20-13-8-14(22)10-2-1-4-21-15(10)17(13)24/h1-2,4,6-8,20,23H,3,5H2
|
| Chemical Name |
7-[2-(3,5-dibromo-4-hydroxyphenyl)ethylamino]quinoline-5,8-dione
|
| Synonyms |
NSC668394; NSC 668394; NSC-668394
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~110.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2119 mL | 11.0595 mL | 22.1190 mL | |
| 5 mM | 0.4424 mL | 2.2119 mL | 4.4238 mL | |
| 10 mM | 0.2212 mL | 1.1060 mL | 2.2119 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
